Author: Quentin Massé

This author has written 113 articles

21/09/2020: Theradiag publishes 2020 H1 results

·         Robust resilience in revenues at €4.9 million driven by Theranostic up +16.5% ·        Continued investment in R&D to drive future growth  ·        North America business accelerates ·        Sound cash position at €1.7 million ·        Launch…

Continue Reading21/09/2020: Theradiag publishes 2020 H1 results

16/09/2020: Theradiag announces the launch of a new range of assays for automated Therapeutic Drug Monitoring of Biologics for use on IDS-iSYS

Croissy-Beaubourg, September, 16, 2020, 8:00 am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for the French PEA-PME personal equity plan), a company specializing in in vitro diagnostics and theranostics, is pleased to announce the…

Continue Reading16/09/2020: Theradiag announces the launch of a new range of assays for automated Therapeutic Drug Monitoring of Biologics for use on IDS-iSYS